Fexagratinib
Term · Oncology and biomedicine · MLC-T-ONC-013573
An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. fexagratinib binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways, and, so, the inhibition of tumor cell proliferation and tumor cell death. FGFR, up-regulated in many tumor cell types, is a receptor tyrosine kinase essential to tumor cellular proliferation, differentiation and survival.
| Identifier | MLC-T-ONC-013573 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | FGFR inhibitor AZD4547 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-013573",
"term": "Fexagratinib",
"field": "Oncology and biomedicine",
"definition": "An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. fexagratinib binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways, and, so, the inhibition of tumor cell proliferation and tumor cell death. FGFR, up-regulated in many tumor cell types, is a receptor tyrosine kinase essential to tumor cellular proliferation, differentiation and survival.",
"synonyms": [
"FGFR inhibitor AZD4547"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/fexagratinib/"
}
Record 7,241 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.